Merit Medical Is Maintained at Buy by Canaccord Genuity

What happened

Canaccord Genuity maintained its Buy rating on Merit Medical and raised the price target to $121.00 per share from $94.00, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A higher price target signals the analyst expects more upside in Merit Medical shares than before. That can draw investor attention to the stock because ratings and targets are watched by people deciding where to put money.

Analyst inference

This is a single analyst update on one medical device company. It reflects Canaccord's view rather than a broad market move, so its effect is likely limited to how investors see Merit Medical specifically.

Analyst inference

What to watch

1. Canaccord Genuity kept its Buy rating on Merit Medical while lifting the share price target to $121.00 from $94.00, a notable increase. Confirmed
2. Watch whether other analysts follow with their own rating or price target changes for Merit Medical, which would show whether the more positive view is spreading. Proposed
3. Watch Merit Medical's future sales and profit reports, because stronger results would support the higher target while weak results could undercut the analyst's view. Analyst inference

Evidence

• Original source link unavailable